Emcure Pharmaceuticals on Thursday announced a royalty-free voluntary licensing agreement with Gilead Sciences Ireland UC, a subsidiary of the California-based Gilead Sciences, to manufacture and supply generic versions of lenacapavir . Lenacapavir is an important medication for HIV prevention and treatment. The agreement aims to bolster access to lenacapavir in 120 countries, with a particular focus on resource-limited nations that experience high rates of HIV infection.
By providing high-quality, low-cost versions of the drug, Emcure hopes to make a meaningful impact in regions where such treatments are urgently needed, the company said in a press release. Satish Mehta, Managing Director and CEO of Emcure Pharmaceuticals, expressed his thoughts on the collaboration, stating, "We are proud to partner with Gilead in this global initiative to expand access to critical HIV medicines." Artificial Intelligence(AI) Java Programming with ChatGPT: Learn using Generative AI By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Artificial Intelligence(AI) Basics of Generative AI : Unveiling Tomorrow's Innovations By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Artificial Intelligence(AI) Generative AI for Dynamic Java Web Applications with ChatGPT By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Artificial Intelligence(AI) Mastering C++ Fundamentals with Generative AI: A Hands-On By - Metla Sudha Sekhar, Developer and Lead Instructo.
